Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drops could replace needles for wet AMD?

NCT ID NCT05637255

Disease control Sponsor: Sylentis, S.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested three different doses of SYL1801 eye drops in 99 people with wet age-related macular degeneration (AMD). The goal was to see if the drops are safe and can improve or maintain vision. Participants used the drops for a set period, and their vision was measured after 42 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SYL1801 eye drops
What this could lead to
If successful, SYL1801 could offer a non-invasive eye drop treatment for wet AMD, potentially reducing the need for frequent injections.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 99 participants. The eye drops may not improve vision as hoped, and long-term safety is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

99 people

The number who actually took part.

Started

Nov 2022

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent * Active subfoveal or juxtafoveal choroidal neovascularization secondary to AMD * Best Corrected Visual Acuity (BCVA) between 70-25 letters (ETDRS) at Screening * Intraretinal or subretinal fluid * Central Subfield Thickness \> 300 µm Exclusion Criteria: * Pregnant or breastfeeding females or those with a positive pregnancy test. * Females of childbearing potential who will not use a medically acceptable contraceptive method * Current, previous chronic or recurrent condition according to the investigator's judgement. * Concomitant treatment or prior ocular procedure or surgery, or alteration of the dose of systemic medications * Concurrent disease in the study eye * Previous treatment with systemic anti-Vascular Endothelial Growing Factor (Anti-VEGF) drugs or pro-VEGF treatments * Concurrent disease in the study eye, other than AMD

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Macular degeneration Neovascular age-related macular degeneration Wet macular degeneration

Contacts and locations

Locations

  • SYL1801 Investigative Site

    Brno, 62500, Czechia

  • SYL1801 Investigative Site

    Chomutov, 43001, Czechia

  • SYL1801 Investigative Site

    Frýdek-Místek, 738 01, Czechia

  • SYL1801 Investigative Site

    Kyjov, 69701, Czechia

  • SYL1801 Investigative Site

    Liberec, 46063, Czechia

  • SYL1801 Investigative Site

    Ostrava, 70200, Czechia

  • SYL1801 Investigative Site

    Prague, 14000, Czechia

  • SYL1801 Investigative Site

    Prague, 17000, Czechia

  • SYL1801 Investigative Site

    Gdansk, 80-809, Poland

  • SYL1801 Investigative Site

    Krakow, 31-070, Poland

  • SYL1801 Investigative Site

    Rzeszów, 35-017, Poland

  • SYL1801 Investigative Site

    Warsaw, 01-258, Poland

  • SYL1801 Investigative Site

    Bratislava, 85107, Slovakia

  • SYL1801 Investigative Site

    Košice, 04011, Slovakia

  • SYL1801 Investigative Site

    Poprad, 05801, Slovakia

  • SYL1801 Investigative Site

    Žilina, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.